Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients [4]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 365-

  Loulergue, Pierre ^a   Callard, Patrice ^a   Bonnard, Philippe ^a   Pialoux, Gilles ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; FATTY LIVER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; DISEASE PROGRESSION; FATTY LIVER; HIV; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; RISK FACTORS;

EID: 34347332367     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d864     Document Type: Letter

References (3)

1. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:373-376.
2. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.
3. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev. 2006;7:197-209.